A Phase 1 first-in-human study of MEDI0680, an anti-PD-1 monoclonal antibody (mAb) in adult patients (pts) with advanced tumors

Date

09 Oct 2016

Session

Poster display

Presenters

Aung Naing

Citation

Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378

Authors

A. Naing1, S. Goel2, B. Curti3, A. Weise4, J.P. Eder5, S. Marshall6, C. Morehouse7, X. Li8, J.J. Karakunnel6, J. Infante9

Author affiliations

  • 1 Department Of Investigational Cancer Therapeutics, MD Anderson Cancer Center, TX 77030 - Houston/US
  • 2 Department Of Medical Oncology, Montefiore Medical Park at Eastchester, New York/US
  • 3 Department Of Medical Oncology, Providence Cancer Center and Earle A. Chiles Research Institute, Portland/US
  • 4 Department Of Oncology, Karmanos Cancer Center, Detroit/US
  • 5 Yale School Of Medicine, Yale Cancer Center, New Haven/US
  • 6 Clinical Development, MedImmune, Gaithersburg/US
  • 7 Translational Medicine, MedImmune, Gaithersburg/US
  • 8 Biostatistics, MedImmune, Gaithersburg/US
  • 9 Phase I Drug Development Unit, Sarah Cannon Research Institute/ Tennessee Oncology, PLLC, Nashville/US
More

Resources

Background

Programmed cell death-1 (PD-1) inhibits T-cell activation. Blocking the PD-1/programmed cell death ligand 1/2 (PD-L1/2) axis has an acceptable safety profile, induces antitumor responses, and provides clinical benefit across tumors. MEDI0680 is a humanized IgG4κ mAb specific for human PD-1 that blocks interaction with PD-L1/2.

Methods

This is an ongoing Phase 1, multicenter, open-label, first-in-human, dose-escalation and expansion study of single-agent MEDI0680 in immunotherapy-naïve pts with advanced solid tumors. Primary objectives are safety/tolerability and maximum tolerated dose (MTD). Secondary objectives include pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity (modified RECIST v1.1).

Results

As of 2 Nov 2015, 58 pts have enrolled across 9 cohorts (0.1–20 mg/kg given Q3W, Q2W, QWx2 then Q2W, or QWx4 then Q2W). MTD was not reached. Treatment-related AEs occurred in 46 pts; most common (>10%) were fatigue (21%), nausea (14%) and arthralgia (14%). Related Grade 3/4 AEs occurred in 10 pts; most common (>1 pt) were anemia, arthralgia and increased AST (3% each). 2 pts discontinued due to related AEs: pyrexia in 1 pt; and increased AST, myasthenia gravis and myositis in 1 pt. There were no Grade 5 related AEs. MEDI0680 had a linear PK profile with dose-proportional increases in peak serum concentration. Median PD-1 receptor occupancy on CD3+ T cells was ≥70% after 1 cycle of 10 or 20 mg/kg Q2W. Increased percentages of Ki67 + , ICOS+ and HLA-DR+ T cells; increased levels of plasma IFNɣ; and enhanced intra-tumor gene expression for these factors were seen after treatment, demonstrating biological activity of MEDI0680. Of 51 evaluable pts, 9 (18%) had an objective response (8 had renal cancer or melanoma), including 1 (2%) complete response (renal cancer). 14 (28%) pts had stable disease as their best response. The recommended dose is 20 mg/kg Q2W, based on PK, PD, safety and efficacy.

Conclusions

MEDI0680 has an acceptable safety profile, with preliminary signs of efficacy. A Phase 1 combination study with durvalumab to test the concept of complete PD-1/PD-L1 axis blockade is ongoing in advanced solid tumors.

Clinical trial identification

NCT02013804 (release date: December 12, 2013)

Legal entity responsible for the study

MedImmune

Funding

MedImmune

Disclosure

A. Naing: Research funding: NCI; EMD Serono; Medimmune; Healios Onc. Nutrition, ATTEROCOR; Amplimmune; ARMO BioSciences; Karyopharm Therapeutics; Incyte; Novartis. B. Curti: Honoraria: Prometheus Speaker Bureau: Prometheus Research funding: Prometheus, Viralytics, Galectin Therapeutics Travel, accommodation, expenses: BMS, Medimmune, AgonOx, Prometheus. J.P. Eder: Honoraria: Merck. S. Marshall: Employment and stock options: Medimmune, Amplimmune. C. Morehouse: Employment: Medimmune Stock/ownership: Medimmune (AstraZeneca). X. Li: Employment: MedImmune. J.J. Karakunnel: Employee of MedImmune and own stock or options in AstraZeneca. Also an employee of MedStar Montgomery Medical Center and Fauquier Hospital. J. Infante: Consulting/advisory: MedImmune Research funding: MedImmune. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings